3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
2
Neoplasms
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Leukemia
1
Interventions
Cyclophosphamide
16
fludarabine
12
Rituximab
4
Antigens, CD19
4
Lenalidomide
3
Immunotherapy, Adoptive
3
Etoposide
3
orelabrutinib
2
Nivolumab
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Methotrexate
2
zanubrutinib
1
relmacabtagene autoleucel
1
prednylidene
1
obinutuzumab
1
merphos
1
ixazomib
1
gemcitabine-oxaliplatin regimen
1
fludarabine phosphate
1
entecavir
1
eltrombopag
1
deltacortene
1
abivertinib
1
Vincristine
1
Transplantation, Autologous
1
Tenofovir
1
Prednisone
1
Pentostatin
1
Melphalan
1
Interleukin-7
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, B-Cell
×
Pentostatin
×
Clear all
NCT00927797
2009-06-25
PERLL
Heidelberg University
Phase 2
Unknown
185 enrolled